Kruglova N., Siniavin A., Gushchin V., Mazurov D. 2021. Different neutralization sensitivity of SARS-CoV-2 cell-to-cell and cell-free modes of infection to convalescent sera. Viruses. 13, 1133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fliedl L., Kaisermayer C. 2011. Transient gene expression in HEK293 and Vero cells immobilised on microcarriers. J. Biotechnol. 153, 15–21.

Article  CAS  PubMed  Google Scholar 

Joyce M.G., Wheatley A.K., Modjarrad K. 2020. Need for speed: from human SARS-CoV-2 samples to protective and efficacious antibodies in weeks. Cell. 182, 7–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krut V.G., Astrakhantseva I.V., Chuvpilo S.A., Efimov G.A., Ambaryan S.G., Drutskaya M.S., Nedospasov S.A. 2022. Antibodies to the N-terminal domain of angiotensin-converting enzyme (ACE2) that block its interaction with SARS-CoV-2 S protein. Dokl. Biochem. Biophys. 502 (1), 1‒4.

Article  CAS  PubMed  Google Scholar 

Krut V.G., Chuvpilo S.A., Astrakhantseva I.V., Kozlovskaya L.I., Efimov G.A., Kruglov A.A., Drutskaya M.S., Nedospasov S.A. 2022. Will peptides help to stop COVID-19? Biochemistry (Moscow). 87, 590–604.

CAS  PubMed  Google Scholar 

Curreli F., Victor S.M.B., Ahmed S., Drelich A., Tong X., Tseng C.K., Hillyer C.D., Debnath A.K. 2020. Stapled peptides based on human angiotensin-converting enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro. mBio. 11, e02451-20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen W.-H., Strych U., Hotez P.J., Bottazzi M.E. 2020. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 7, 61–64.

Article  PubMed  PubMed Central  Google Scholar 

Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G.F., Tan W., Wu G., Xu M., Lou Z., Huang W., Xu W., Huang B., Wang H., Wang W., Zhang W., Li N., Xie Z., Ding L., You W., Zhao Y., Yang X., Liu Y., Wang Q., Huang L., Yang Y., Xu G., Luo B., Wang W., Liu P., Guo W., Yang X. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 21, 39–51.

Article  CAS  PubMed  Google Scholar 

Wu Z., Hu Y., Xu M., Chen Z., Yang W., Jiang Z., Li M., Jin H., Cui G., Chen P., Wang L., Zhao G., Ding Y., Zhao Y., Yin W. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infec. Dis. 21, 803–812.

Article  CAS  Google Scholar 

Kozlovskaya L.I., Piniaeva A.N., Ignatyev G.M., Gordeychuk I.V., Volok V.P., Rogova Y.V., Shishova A.A., Kovpak A.A., Ivin Y.Yu., Antonova L.P., Mefyod K.M., Prokosheva L.S., Sibirkina A.S., Tarasova Y.Yu., Bayurova E.O., Gancharova O.S., Illarionova V.V., Glukhov G.S., Sokolova O.S., Shaitan K.V., Moysenovich A.M., Gulyaev S.A., Gulyaeva T.V., Moroz A.V., Gmyl L.V., Ipatova E.G., Kirpichnikov M.P., Egorov A.M., Siniugina A.A., Ishmukhametov A.A. 2021. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg. Microbes Infect. 10, 1790–1806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg AL.; Gam-COVID-Vac Vaccine Trial Group. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 397 (10275), 671–681.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knoll M.D., Wonodi C. 2021. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 397, 72–74.

Article  CAS  PubMed  Google Scholar 

Stephenson K.E., Le Gars M., Sadoff J., de Groot A.M., Heerwegh D., Truyers C., Atyeo C., Loos C., Chandrashekar A., McMahan K., Tostanoski L.H., Yu J., Gebre M.S., Jacob-Dolan C., Li Z., Patel S., Peter L., Liu J., Borducchi E.N., Nkolola J.P., Souza M., Tan C.S., Zash R., Julg B., Nathavitharana R.R., Sh-apiro R.L., Azim A.A., Alonso C.D., Jaegle K., Ansel J.L., Kanjilal D.G., Guiney C.J., Bradshaw C., Tyler A., Makoni T., Yanosick K.E., Seaman M.S., Lauffenburger D.A., Alter G., Struyf F., Douoguih M., Van Hoof J., Schuitemaker H., Barouch D.H. 2021. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 325 (15), 1535‒15445.

Article  CAS  PubMed  Google Scholar 

Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., Jia S.Y., Jiang H.D., Wang L., Jiang T., Hu Y., Gou J.B., Xu S.B., Xu J.J., Wang X.W., Wang W., Chen W. 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 395 (10240), 1845‒1854.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., Oliveira T.Y., Yang Z., Abernathy M.E., Huey-Tubman K.E., H-urley A., Turroja M., West K.A., Gordon K., Millard K.G., Ramos V., Da Silva J., Xu J., Colbert R.A., Patel R., Dizon J., Unson-O’Brien C., Shimeliovich I., Gazumyan A., Caskey M., Bjorkman P.J., Casellas R., Hatziioannou T., Bieniasz P.D., Nussenzweig M.C. 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 592, 616–622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations.

Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., Danilenko E.D., Imatdinov I.R., Nechaeva E.A., Pyankov O.V., Pyankova O.G., Susloparov I.M., Taranov O.S., Gudymo A.S, Danilchenko N.V., Sleptsova E.S., Bodnev S.A., Onkhonova G.S., Petrov V.N., Moiseeva A.A., Torzhkova P.Yu., Pyankov S.A., Tregubchak T.V., Antonets D.V., Gavrilova E.V., Maksyutov R.A. 2021. Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2. Annals RAMS. 76, 5–19.

Article  Google Scholar 

Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., Usova S.V., Danilenko E.D., Nechaeva E.A., Pyankov O.V., Pyankova O.G., Gudymo A.S., Bodnev S.A., Onkhonova G.S., Sleptsova E.S., Kuzubov V.I., Ryndyuk N.N., Ginko Z.I., Petrov V.N., Moiseeva A.A., Torzhkova P.Yu., Pyankov S.A., Tregubchak T.V., Antonec D.V, Gavrilova E.V., Maksyutov R.A. 2021. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russ. J. Inf. Immun. 11, 283–296.

Google Scholar 

Kudriavtsev A.V., Vakhrusheva A.V., Novoseletsky V.N., Bozdaganyan M.E., Shaitan K.V., Kirpichnikov M.P., Sokolova O.S. 2022. Immune escape associated with RBD Omicron mutations and SARS-CoV-2 evolution dynamics. Viruses. 14, 1603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rashedi R., Samieefar N., Masoumi N., Mohseni S., Rezaei N. 2022. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J. Med. Virol. 94, 1294–1299.

Article  CAS  PubMed  Google Scholar 

Ng K.W., Faulkner N., Finsterbusch K., Wu M., Harvey R., Hussain S., Greco M., Liu Y., Kjaer S., Swanton C., Gandhi S., Beale R., Gamblin S.J., Cherepanov P., McCauley J., Daniels R., Howell M., Arase H., Wack A., Bauer D.L.V., Kassiotis G. 2022. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715.

Claireaux M., Caniels T.G., de Gast M., Han J., Guerra D., Kerster G., van Schaik B.D.C., Jongejan A., Schriek A.I., Grobben M., Brouwer P.J.M., van der Straten K., Aldon Y., Capella-Pujol J., Snitselaar J.L., Olijhoek W., Aartse A., Brinkkemper M., Bontjer I, Burger J.A., Poniman M., Bijl T.P.L., Torres J.L., Copps J., Martin I.C., de Taeye S.W., de Bree G.J., Ward A.B., Sliepen K., van Kampen A.H.C., Moerland P.D., Sanders R.W., van Gils M.J. 2022. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nat. Commun. 13, 4539.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zoufaly A., Poglitsch M., Aberle J.H., Hoepler W., Seitz T., Traugott M., Grieb A., Pawelka E., Laferl H., Wenisch C., Neuhold S., Haider D., Stiasny K., Bergthaler A., Puchhammer-Stoeckl E., Mirazimi A., Montserrat N., Zhang H., Slutsky A.S., Penninger J.M. 2020. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8, 1154–1158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bibilashvili R.Sh., Sidorova M.V., Dudkina U.S., Palkeeva M.E., Molokoedov A.S., Kozlovskaya L.I., Egorov A.M., Ishmukhametov A.A., Parfyonova Y.V. 2021. Peptide inhibitors of the interaction of the SARS-CoV-2 receptor-binding domain with the ACE2 cell receptor. Biomed. Khim. 67, 244–250.

Article  CAS  PubMed  Google Scholar 

Zhang G., Pomplun S., Loftis A.R., Tan X., Loas A. Pentelute B.L. 2020. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 spike RBD. bioRxiv. 2020.03.19.999318. https://doi.org/10.1101/2020.03.19.999318

Karoyan P., Vieillard V., Gómez-Morales L., Odile E., Guihot A., Luyt C.E., Denis A., Grondin P., Lequin O. 2021. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 4, 197.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larue R.C., Xing E., Kenney A.D., Zhang Y., Tuazon J.A., Li J., Yount J.S., Li P.K., Sharma A. 2021. Rationally designed ACE2-derived peptides inhibit SARS-CoV-2. Bioconjug. Chem. 32, 215–223.

Article  CAS  PubMed  Google Scholar